Literature DB >> 16712667

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

Marie-Hélène Gannagé-Yared1, Florence Fares, Michelle Semaan, Simon Khalife, Selim Jambart.   

Abstract

OBJECTIVE: The relationship between osteoprotegerin (OPG) and lipid profile, insulin sensitivity, adipocytokines and sex steroids has been poorly studied and subject to controversy. The purpose of this study was to look at the correlates of OPG in an elderly male population.
DESIGN: One hundred and fifty-one nondiabetic, elderly Lebanese men (age range 50-83) were recruited in this cross-sectional study based on voluntary enrolment. MEASUREMENTS: In all the subjects, serum OPG levels were measured and related to clinical parameters (age, waist, body mass index (BMI), systolic and diastolic blood pressure), as well as to metabolic and hormonal parameters. The following fasting laboratory measurements were performed: plasma glucose and insulin levels, total cholesterol, triglycerides and HDL cholesterol, adiponectin, leptin, as well as sex steroids (testosterone, SHBG, free androgen index, ooestradiol, DHEAS), GH and IGF-1. QUICKI index was calculated as a measure of insulin sensitivity.
RESULTS: OPG levels were significantly correlated with age (r = 0.28, P < 0.0001) but not with BMI, waist, systolic or diastolic blood pressure. There was a trend towards higher OPG levels in subjects without, compared to subjects with the metabolic syndrome (3.58 +/- 1.28 vs. 3.26 +/- 1.04 pmol/l, P = 0.09). OPG was negatively correlated with fasting glucose and triglyceride levels (r = -0.18, P = 0.031 and r = -0.19, P = 0.02, respectively) and positively correlated with the QUICKI index (r = 0.17, P = 0.033), HDL cholesterol (r = 0.21, P = 0.009) and adiponectin levels (r = 0.27, P = 0.001). No significant correlations were reported with total or LDL cholesterol levels and with leptin levels. After adjustment for age, OPG is still correlated with triglycerides (r = -0.19, P = 0.02), glucose (r = -0.21, P = 0.011) and adiponectin (r = 0.19, P = 0.02). Finally, OPG was positively associated with SHBG (r = 0.31, P < 0.001) and negatively associated with free androgen index (r =-0.346, P < 0.001); both correlations persisted after adjustment for age (r = 0.21, P = 0.009 and r = -0.23, P = 0.005, respectively). No significant correlation was found between OPG and oestradiol levels while a weak negative correlation was demonstrated with DHEAS (r = -0.18, P = 0.025). Also, no significant correlation was found between OPG and GH or IGF-1 values. In a multiple regression analysis with a stepwise model, the main determinants of OPG were free androgen index and adiponectin (P < 0.0001 and P = 0.015, respectively).
CONCLUSION: Our results show that circulating OPG levels are favourably associated with some components of the metabolic syndrome. Also, for the first time, an association between OPG and adiponectin is described. Finally, the negative correlation we found between OPG and free androgen index may suggest a potential role of OPG in the increase in cardiovascular disease related to ageing and sex steroid deficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712667     DOI: 10.1111/j.1365-2265.2006.02522.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  21 in total

1.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

2.  Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Pamela Ouyang; Dhananjay Vaidya; Adrian Dobs; Sherita Hill Golden; Moyses Szklo; Susan R Heckbert; Peter Kopp; Susan M Gapstur
Journal:  Atherosclerosis       Date:  2008-09-06       Impact factor: 5.162

Review 3.  Adipose tissue dysfunction and its effects on tumor metabolism.

Authors:  Jonathan Diedrich; Halina Chkourko Gusky; Izabela Podgorski
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

4.  Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.

Authors:  Romina di Giuseppe; Ronald Biemann; Janine Wirth; Juliane Menzel; Berend Isermann; Gabriele I Stangl; Andreas Fritsche; Heiner Boeing; Matthias B Schulze; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2016-06-15       Impact factor: 8.082

5.  Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.

Authors:  Goran Loncar; Biljana Bozic; Vojkan Cvorovic; Zoran Radojicic; Sinisa Dimkovic; Natasa Markovic; Nenad Prodanovic; Toplica Lepic; Biljana Putnikovic; Vera Popovic-Brkic
Journal:  Endocrine       Date:  2009-11-20       Impact factor: 3.633

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 7.  Osteoprotegerin, vascular calcification and atherosclerosis.

Authors:  Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-10-09       Impact factor: 5.162

Review 8.  The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.

Authors:  Daniela-Eugenia Malliga; Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2011-09-02

9.  Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.

Authors:  Jong Suk Park; Min Ho Cho; Ji Sun Nam; Jeong Seon Yoo; Chul Woo Ahn; Bong Soo Cha; Kyung Rae Kim; Hyun Chul Lee
Journal:  Eur J Endocrinol       Date:  2010-10-20       Impact factor: 6.664

10.  Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes.

Authors:  Atsushi Aoki; Miho Murata; Tomoko Asano; Aki Ikoma; Masami Sasaki; Tomoyuki Saito; Taeko Otani; Sachimi Jinbo; Nahoko Ikeda; Masanobu Kawakami; San-e Ishikawa
Journal:  Cardiovasc Diabetol       Date:  2013-01-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.